Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00453193 · ClinicalTrials.gov registry record · Phase 2
Alemtuzumab and Pentostatin In T-cell Neoplasms
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00453193: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00453193 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00453193, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if giving pentostatin with alemtuzumab can help to control T-cell malignancy. The safety of this combination therapy will also be studied.
Interventions
- DRUG Alemtuzumab
- DRUG Pentostatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2004-09 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00453193
The ClinicalTrials.gov registry entry for NCT00453193 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alemtuzumab is the first listed.
NCT00453193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00453193 about?
NCT00453193 is a clinical study titled "Alemtuzumab and Pentostatin In T-cell Neoplasms". The goal of this clinical research study is to learn if giving pentostatin with alemtuzumab can help to control T-cell malignancy. The safety of this combination therapy will also be studied.
What is the current status of trial NCT00453193?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2004-09. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00453193?
The interventions under investigation include: Alemtuzumab (DRUG), Pentostatin (DRUG).
Who is sponsoring clinical trial NCT00453193?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.